Amicus Therapeutics (FOLD) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
He observes that additional stockholder and class action complaints related to the BioMarin merger could expose Amicus Therapeutics and its directors to costly and uncertain litigation. Such lawsuits may delay or derail the merger process, divert management’s focus from operations, and create incremental financial and strategic risk for the company.
He believes the inherently unpredictable nature of these potential legal proceedings heightens execution risk around the merger timeline and terms. Prolonged disputes or adverse rulings could weaken Amicus Therapeutics’ negotiating position, strain resources, and negatively impact shareholder value.
The average FOLD stock price target is $14.08, implying -1.81% downside potential.
To learn more about Amicus Therapeutics’ risk factors, click here.